ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Abstract

Background Overexpression of ABC transporters is a big challenge on cancer therapy which will lead cancer cells resistance to a series of anticancer drugs. Gedatolisib is a dual PI3K and mTOR inhibitor which is under clinical evaluation for multiple types of malignancies, including colorectal cancer. The growth inhibitory effects of gedatolisib on colorectal cancer cells have been specifically studied. However, the role of ABC transporters on gedatolisib resistance remained unclear. In present study, we illustrated the role of ABC transporters on gedatolisib resistance in colorectal cancer cells. Methods Cell viability investigations of gedatolisib on colorectal cancer cells were determined by MTT assays. The verapamil and Ko143 reversal studies were determined by MTT assays as well. ABCB1 and/or ABCG2 siRNA interference assays were conducted to verify the role of ABCB1- and ABCG2-overexpression on gedatolisib resistance. The accumulation assays of gedatolisib were conducted using tritium-labeled paclitaxel and mitoxantrone. The effects of gedatolisib on ATPase activity of ABCB1 or ABCG2 were conducted using PREDEASY ATPase Kits. The expression level of ABCB1 and ABCG2 after gedatolisib treatment were conducted by Western blotting and immunofluorescence assays. The well-docked position of gedatolisib with crystal structure of ABCB1 and ABCG2 were simulated by Autodock vina software. One-way ANOVA was used for the statistics analysis. Results Gedatolisib competitively increased the accumulation of tritium-labeled substrate-drugs in both ABCB1- and ABCG2-overexpression colorectal cancer cells. Moreover, gedatolisib significantly increased the protein expression level of ABCB1 and ABCG2 in colorectal cancer cells. In addition, gedatolisib remarkably simulated the ATPase activity of both ABCB1 and ABCG2, suggesting that gedatolisib is a substrate drug of both ABCB1 and ABCG2 transporters. Furthermore, a gedatolisib-resistance colorectal cancer cell line, SW620/GEDA, was selected by increasingly treatment with gedatolisib to SW620 cells. The SW620/GEDA cell line was proved to resistant to gedatolisib and a series of chemotherapeutic drugs, except cisplatin. The ABCB1 and ABCG2 were observed overexpression in SW620/GEDA cell line. Conclusions These findings suggest that overexpression of ABCB1 and ABCG2 may restrict the efficacy of gedatolisib in colorectal cancer cells, while co-administration with ABC transporter inhibitors may improve the potency of gedatolisib.

Novel 2-Aminobenzothiazole Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents

“…The study found that the IC 50 values for doxorubicin and gedatolisib were 16.61 and 16.46 μM against A549 cancer cell lines (Table ), respectively, while the reported IC 50 for gedatolisib was 9.05 μM. , The reported IC 50 for doxorubicin against A549 was 0.071 μM. − The most active synthesized compound (OMS14) was tested against cancer enzymes other than PI3Kγ, and the result is shown in Table .…”

The Potential of Low Press and Hypoxia Environment in Assisting Pan-cancer Treatment

“…ABCB1 and SOD2 were reported to be directly regulated by HIF-1, so they may play a key role in the adjuvant intervention of LPH. ABCB1 is regulated by HIF-1α in ovarian cancer cells 45 , and lactate depletion in tumors can also significantly inhibit ABCB1 expression 46 , while some studies have also suggested that its inhibitors can attenuate multidrug resistance in tumors after treatment [47][48][49][50] . In addition, the increased expression of SOD2, an important antioxidant enzyme superoxide dismutase 2, stabilizes HIF-2α in an H2O2-dependent manner, promotes the expression of core stem cell genes (i.e., Oct4 and SOX2), and increases the cancer stem cell (CSC) subpopulation, tumorigenicity, and invasiveness of breast cancer cells 51 .…”

Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones

“…BCRP has important functions in excluding antitumor drugs from various cancer cells, being a significant therapeutic barrier. Since it has subspecies polyspecificity and is present in many tissues, protein is an important factor in resistance to therapy [ 170 , 171 , 172 ]. In some tumor formations, ABCG2 is strongly overexpressed, which is correlated with unfavorable clinical outcomes for these tumors [ 173 ].…”